Table I.
Differentially expressed cytokines (fold change ≥2 or ≤0.5) were associated with regulation of apoptosis, angiogenesis, autoimmunity/inflammation, and the cell cycle after the ORFV infection.
| Cytokine | F-value | P-value | Fold change | Mean (ORFV-infected, n=3) | Mean (control, n=3) | Functional classification |
|---|---|---|---|---|---|---|
| IL-15 | 0.000 | 0.184 | 2,189.610 | 827.6 | 0.4 | Apoptosis, angiogenesis, and autoimmunity/inflammation |
| IL-13 | 0.000 | 0.342 | 1,869.543 | 402.6 | 0.2 | Autoimmunity/inflammation |
| RAGE | 0.000 | 0.190 | 562.576 | 49.2 | 0.1 | MAPK signaling, ERK1/2 and p53/TP53 signaling and NF-κB |
| EDAR | 0.000 | 0.282 | 372.656 | 3,807.4 | 10.2 | Apoptosis and NF-κB |
| MIG | 0.000 | 0.114 | 353.760 | 359.9 | 1.0 | Transfection factor and TOLLR |
| TRAIL | 0.000 | 0.250 | 289.072 | 321.7 | 1.1 | Apoptosis, angiogenesis, and cell cycle |
| BLC (CXCL13) | 0.000 | 0.133 | 219.855 | 111.9 | 0.5 | Apoptosis and autoimmunity/inflammation |
| IL-7 | 0.000 | 0.306 | 200.395 | 185.2 | 0.9 | Apoptosis and autoimmunity/inflammation |
| CD27 | 0.000 | 0.080 | 185.302 | 471.6 | 2.5 | Apoptosis, Autoimmunity/inflammation, and cell cycle |
| Tryptase ε | 0.000 | 0.197 | 180.294 | 1,374.2 | 7.6 | Immune response |
| CCL6 | 0.000 | 0.117 | 156.765 | 2,374.0 | 15.1 | Chemokine |
| DLL4 | 0.002 | 0.018 | 64.517 | 6,938.8 | 107.6 | Angiogenesis, Notch |
| Fractalkine | 0.001 | 0.370 | 48.519 | 15,760.2 | 324.8 | Immune response |
| TARC | 0.001 | 0.198 | 36.512 | 56.8 | 1.6 | Autoimmunity/inflammation |
| DAN | 0.000 | 0.184 | 34.164 | 2,324.7 | 68.0 | Autoimmunity/inflammation and cell cycle |
| VEGF-D | 0.001 | 0.317 | 32.318 | 46.4 | 1.4 | Notch, angiogenesis, and cell cycle |
| OX40 ligand | 0.002 | 0.205 | 25.443 | 245.5 | 9.6 | Apoptosis, autoimmunity/inflammation |
| Prostasin | 0.013 | 0.258 | 20.023 | 2,087.1 | 104.2 | Trypsin-like cleavage specificity |
| I-TAC | 0.063 | 0.071 | 11.777 | 96.6 | 8.2 | Transfection factor, TOLLR, apoptosis, angiogenesis, and autoimmunity/inflammation |
| Leptin | 0.006 | 0.429 | 11.208 | 960.1 | 85.7 | Apoptosis, autoimmunity/inflammation, and angiogenesis |
| TIM-1 | 0.071 | 0.192 | 9.311 | 111.9 | 12.0 | Immune response |
| IL-21 | 0.299 | 0.002 | 9.142 | 91.7 | 10.0 | Autoimmunity/inflammation |
| TREM-1 | 0.272 | 0.021 | 9.061 | 42.5 | 4.7 | Chemokine |
| H60 | 0.089 | 0.044 | 7.084 | 95.2 | 13.4 | MHC I |
| TPO | 0.370 | 0.017 | 6.500 | 192.7 | 29.6 | Growth factor |
| KC | 0.551 | 0.002 | 5.892 | 234.5 | 39.8 | Angiogenesis, autoimmunity/inflammation |
| TACI | 0.006 | 0.150 | 5.619 | 78.9 | 14.0 | Apoptosis |
| ALK-1 | 0.638 | 0.005 | 3.444 | 67.2 | 19.5 | Protein kinase |
| BAFF R | 0.058 | 0.004 | 3.272 | 100.8 | 30.8 | Immune response |
| Osteoactivin | 0.291 | 0.035 | 3.211 | 1,234.1 | 384.4 | Growth factor |
| Pentraxin 3 | 0.012 | 0.164 | 3.115 | 5,956.9 | 1,912.4 | Apoptosis and autoimmunity/inflammation |
| Granzyme B | 0.131 | 0.096 | 2.767 | 406.0 | 146.7 | Apoptosis and autoimmunity/inflammation |
| Prolactin | 0.805 | 0.069 | 2.419 | 2,615.6 | 1,081.4 | Insulin1 and apoptosis |
| VEGF R1 | 0.841 | 0.007 | 2.236 | 942.3 | 421.4 | Angiogenesis and protein kinase |
| Neprilysin | 0.698 | 0.081 | 2.184 | 1,059.8 | 485.2 | Apoptosis and angiogenesis |
| CD30 | 0.049 | 0.190 | 2.152 | 110.5 | 51.4 | Apoptosis and angiogenesis |
| Axl | 0.874 | 0.093 | 0.469 | 682.5 | 1,455.8 | Protein kinase, apoptosis, and cell cycle |
| CXCL16 | 0.252 | 0.010 | 0.389 | 28.8 | 74.2 | Chemokine |
| ANG-3 | 0.967 | 0.031 | 0.369 | 120.1 | 325.4 | Tyrosine kinase signaling pathway |
| MMP10 | 0.630 | 0.035 | 0.369 | 39.6 | 107.4 | Tumor metastasis |
| IFN-γ R1 | 0.225 | 0.034 | 0.316 | 5.3 | 16.8 | The JAK/STAT signaling pathway |
| VEGF-B | 0.063 | 0.027 | 0.080 | 9.1 | 113.0 | Angiogenesis and cell cycle |
ORFV, Orf virus; VEGF, vascular endothelial growth factor; DLL4, delta-like canonical Notch ligand 4; BLC, B lymphocyte chemoattractant; IL, interleukin; RAGE, receptor of advanced glycosylation end product; MMP10, matrix metallopeptidase 10.